Multiple Ascending Doses (MAD) of AZD3199 Given Once Daily as Inhaled Formulation Via Turbuhaler to Healthy Men

A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel-group, Single-centre Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD3199 (a B2-agonist) Given Once Daily as Inhaled Formulation Via Turbuhaler to Healthy Men

The purpose of this study is to investigate the safety and tolerability of multiple once daily ascending doses of AZD3199 in healthy men

Inclusion Criteria:

• BMI 19-30, weight 60-100 kg
• Non/ex-smokers, Non/ex-nicotine users

Exclusion Criteria:

• Any clinically significant disease or disorder
• Any clinically relevant abnormal findings at screening examinations
• Use of any prescribed or non-prescribed medication